Background-We hypothesized that patients with heart failure (HF) who recover left ventricular function (HF-Recovered) have 
R
ecovery of left ventricular (LV) function is a primary goal of therapy in heart failure (HF) with reduced ejection fraction (HF-REF). Pharmacological therapy, coronary revascularization, cardiac resynchronization, and ventricular assist devices (VADs) are all used to achieve this objective. [1] [2] [3] [4] [5] [6] However, little is known about the natural history, prognosis, and need for continued longterm therapies in patients when there is recovery of LV function (eg, HF and recovered ejection fraction [HF-Recovered]). [7] [8] [9] [10] In fact, many of these patients continue HF-REF treatment, whereas others may discontinue therapy or become misclassified as having HF with preserved ejection fraction (HF-PEF).
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Increases in EF and improvements in LV geometry in response to therapy may result in a milder HF phenotype and a prognostic improvement. This favorable myocardial response has been referred to as reverse remodeling or myocardial remission. 12 Understanding the clinical and biological features of the HF-Recovered population is central to understanding what predicts reverse remodeling and ultimately complete recovery. This understanding is particularly relevant in the field of mechanical circulatory support, where using LV assist devices as a bridge to recovery is an evolving clinical practice and the focus of intense investigation. 13 We sought to characterize the HF-Recovered population, which includes a spectrum of patients with reverse remodeling, and compare it with the HF-REF and HF-PEF populations. We hypothesized that the HF-Recovered population has a distinct clinical phenotype, biology, and prognosis. We explored this hypothesis by analyzing baseline clinical data, biomarker data representing several key biological pathways (neurohormonal activation, myocyte stress and injury, oxidative stress, inflammation, and vascular remodeling), and long-term clinical outcomes from a diverse, outpatient-based multicenter HF cohort.
Methods
Study Population
The Penn Heart Failure Study is a prospective cohort study of patients referred to 3 US HF specialty centers-the University of Pennsylvania (Philadelphia, PA), Case Western Reserve University (Cleveland, OH), and the University of Wisconsin (Madison, WI)-with the use of a harmonized protocol. An institutional review committee at each participating center approved the study protocol; each participant gave written informed consent. The inclusion criteria were referral to an outpatient HF specialty clinic at these centers for evaluation and treatment of HF and the absence of a noncardiac condition likely leading to mortality within 6 months. All new referrals at each center were directly screened for eligibility by study coordinators in the clinics through direct review of individual medical records. Eligible patients were then approached at the time of their clinic visit and offered participation. Over the course of the study, approximately one third of the eligible patients consented to participate. Participants were recruited from 2003 to 2012.
14 At the time of study entry, detailed clinical data were obtained with a standardized questionnaire administered to the patient and treating physician, with verification via medical records. The primary cause of HF and the presence or absence of comorbidities were defined by the HF cardiologist at each center on the basis of available clinical data. Venous blood samples were obtained at enrollment, processed, and stored at −80°C until the time of assay. Two-dimensional transthoracic echocardiography was performed in all participants at an Intersocietal Commission for the Accreditation of Echocardiography Laboratories-accredited laboratory as part of routine clinical practice. The median time between echocardiogram measurement and study enrollment was 71 days. A level III-certified echocardiographer estimated LV EF at each center. Dedicated research personnel obtained follow-up data on all participants every 6 months according to the study protocol, either through in-person encounters in the clinic or through telephone encounters. At each follow-up encounter, study end points (death, VAD, transplantation, hospitalizations) were captured and verified through death certificates, medical records, or contact with patients' family members. Hospitalizations were classified as cardiovascular or noncardiovascular on the basis of medical record adjudication of admission diagnoses by an HF expert. Participants were censored at the time of the last follow-up.
Classification of HF Subgroups
For this analysis, participants were classified into 3 categories of HF: HF-REF, HF-PEF, or HF-Recovered. Patients were classified as having HF-REF if the enrollment echocardiogram showed an EF <50%. Patients with normal LV function as defined by an EF ≥50% were further classified as having HF-PEF versus HF-Recovered on the basis of additional retrospective chart review of prior echocardiograms. Patients who had only previously documented EF ≥50% were considered to have HF-PEF, and those with a documented history of EF <50% were considered to have HF-Recovered. Patients with incomplete baseline information were excluded. Additionally, patients with hypertrophic cardiomyopathy and infiltrative cardiomyopathies were excluded. The natural history of these conditions is often distinct from that of HF-PEF and, in cases such as amyloidosis, particularly poor. Therefore, we felt that inclusion of these subjects would be inappropriate and could bias the results toward worse outcomes in HF-PEF. Patients with normal EF on enrollment but no prior documentation of the EF were excluded from this study.
Biomarker Assays
All biomarkers were measured from banked plasma obtained at the time of study enrollment. Brain natriuretic peptide (BNP), troponin I, high-sensitivity C-reactive protein, uric acid, and creatinine were measured with standard ARCHITECT immunoassays (Abbott Laboratories, Abbott Park, IL). Placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor-1 (sFlt-1), and myeloperoxidase were measured with prototype ARCHITECT chemiluminescent microparticle-based immunoassays (Abbott Laboratories). Soluble Toll-like receptor-2 (ST2) was measured with a high-sensitivity sandwich monoclonal immunoassay (Presage ST2 Assay, Critical Diagnostics, San Diego, CA). 15 
Statistical Methods
Characteristics of the study participants at enrollment were summarized with the use of standard descriptive statistics; ANOVA, Kruskal-Wallis tests, and Fisher exact tests were used to compare characteristics between HF categories. For certain covariates such as biomarker levels, data may have been available for only a subset of patients. In these situations, the relevant size of the available subset was noted in the corresponding table. Imputation was not performed for missing data. Among participants with serum biomarkers collected at enrollment, biomarker levels were summarized using medians with 25th and 75th percentiles. Kruskal-Wallis rank-sum tests were used to compare biomarker levels between HF categories. A Kaplan-Meier curve was used to summarize the survival distribution for the composite terminal event of all-cause death, cardiac transplantation, or VAD placement. Cox regression models were used to determine the relative hazard of the composite terminal event between HF categories. A nonparametric, recurrent-event survival curve was used to summarize the survival distribution for cardiac hospitalization. 16 Recurrent-event models were used to determine the relative hazard of cardiac hospitalization between HF categories. A joint frailty model was used to accommodate informative censoring by the composite terminal event. 17 Adjustment variables were selected a priori and included age, sex, race (white, black, or other), HF type (ischemic or nonischemic), history of chronic kidney disease, history of hypertension, and enrollment site. All analyses were completed with R 3.0.1 (R Development Core Team, Vienna, Austria), including the survival, survrec, and frailtypack extension packages.
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Results
Of the 2136 patients in our cohort, 163 patients had insufficient baseline data to include in this analysis, 65 patients had a history of hypertrophic cardiomyopathy or infiltrative heart diseases, and 30 patients had a history of LV assist device implantation or heart transplantation. Thus, 1878 patients met study criteria, but 57 patients with an EF ≥50% were excluded because of a lack of prior echocardiogram and EF data. The final 1821 patients in our study cohort were categorized as shown in Figure 1 : 1523 patients had HF-REF (mean EF, 27%), 122 patients had HF-PEF (mean EF, 62%), and 176 patients had HF-Recovered EF (mean EF, 57%). The HF-Recovered EF group median EF nadir was 28% (25th and 75th percentiles, 20% and 35%) before enrollment in our cohort. The median difference between enrollment EF and EF nadir (ie, the amount of recovery) was 28% (25th and 75th percentiles, 20% and 35%) during a median time period of 29 months (25th and 75th percentiles, 16 and 53 months).
Demographics and Medical History
Baseline clinical characteristics for each of these subgroups are shown in Table 1 . HF-Recovered patients were younger than HF-PEF patients and similar in age to patients with HF-REF.
HF-Recovered patients also had a lower prevalence of coronary artery disease requiring revascularization and consequently fewer with an ischemic origin than HF-REF. 
Clinical Measures
Mean blood pressure in the HF-Recovered group was higher than in HF-REF but lower than in the HF-PEF population. There were no significant differences between mean serum sodium levels across the groups. Table 2 describes baseline biomarker data in each of the HF categories. Serum creatinine, BNP, troponin I, and sFlt-1 were lowest in the HF-Recovered group and highest in the HF-REF group. Uric acid was also lowest in the HF-Recovered group. There was no difference in PlGF, high-sensitivity C-reactive protein, or myeloperoxidase across HF groups. However, nearly a third (30%) of HF-Recovered patients still had a BNP level above the 95th percentile (135 pg/mL), suggesting persistent neurohormonal activation. 19 Nearly half of the HF-Recovered group had evidence of oxidative stress, with 47% of patients having uric acid levels above the 95th percentile (2.6-6 mg/dL for women and 3.5-7.2 mg/dL for men). 20 Detectable troponin I levels were seen in 44% of the HF-Recovered patients. Additionally, sFlt-1 was lowest in the HF-Recovered population, but 26% of that population was still above the 95th percentile (322.9 pg/mL). 21 ST2 was highest in the HF-PEF population but lowest in the HF-REF group, with 22% of the HF-Recovered population above the 95th percentile (37.9 ng/mL). 22 Overall, HF-Recovered patients were biochemically distinct from HF-PEF and HF-REF patients and had the lowest levels of risk markers.
Biochemical profiles
Adverse Cardiovascular Outcomes
The 1821 participants were followed up for a maximum of 8.9 years and a median of 3.6 years. Of these participants, 507 experienced a terminal event, including 335 deaths, 129 transplantations, and 43 VAD placements. Figure 2A compares the probability of reaching these discrete events over time across HF categories. In unadjusted Cox models (Table 3) , the hazard ratio for all-cause death, cardiac transplantation, or VAD placement in the HF-REF versus the HF-Recovered group was 4.1 (95% confidence interval, 2.4-6.8; P<0.001). The unadjusted hazard ratio for the HF-PEF versus the HF-Recovered group was 2.3 (95% confidence interval, 1.2-4.5; P=0.013). In multivariable-adjusted models (age, sex, race, HF type, history of chronic kidney disease, history of hypertension, and site), these associations remained statistically significant (Table 3) . A sensitivity analysis restricted to all-cause mortality provided similar results (data not shown). Overall, both the HF-REF and HF-PEF subgroups had a substantially increased risk of death, transplantation, or VAD placement compared with the HF-Recovered subgroup. However, it is important to note that nearly 20% of the HF-Recovered population suffered from death, cardiac transplantation, or VAD by 8 years of follow-up.
Among the 964 subjects who experienced ≥1 hospitalizations in the cohort, there were 2453 total hospitalizations: 406 participants had 1 hospitalization; 224 had 2 hospitalizations; 118 had 3 hospitalizations; 87 had 4 hospitalizations; and 129 had ≥5 hospitalizations. Surprisingly, the HF-Recovered group had a substantial number of hospitalizations that was similar to the incidence in the HF-Preserved group ( Figure 2B ). With the use of recurrent-event models (Table 4) , the unadjusted hazard ratio for cardiac hospitalization in the HF-PEF versus the 
Discussion
The current HF paradigm is to classify patients into 1 of 2 categories: HF-REF and HF-PEF. However, it is possible that a number of HF-Recovered patients are being erroneously classified as having HF-PEF. Punnoose et al 11 reported that nearly 70% of patients with normal EF on echocardiography in their tertiary care referral center registry had had a reduced EF Number at risk Figure 2 . Probability of all-cause death, cardiac transplantation, or ventricular assist device (VAD) placement for all participants (A) and probability of cardiac hospitalization for all participants (B) from time of referral to an outpatient heart failure specialty care center.
by guest on April 22, 2017 http://circ.ahajournals.org/ Downloaded from previously and suggested that this group of patients represents a separate clinical entity. The HF-Recovered patient, we also believe, represents a third, distinct category along the continuum of HF. Our data suggest that the HF-Recovered population has different demographics, comorbidities, and symptom severity compared with the HF-REF and HF-PEF populations.
In this study, we compared key biological pathways across these populations by using both traditional biomarkers (BNP, uric acid, myeloperoxidase, high-sensitivity C-reactive protein, troponin) and novel biomarkers such as ST2, PlGF, and sFlt-1. ST2, a receptor involved in a cardioprotective signaling system in response to myocyte stress, has been shown to be an independent predictor of HF outcomes. 15 Additionally, we compared evidence of vascular remodeling across HF groups by measuring plasma levels of the angiogenic ligand PlGF and the circulating form of its target receptor, sFlt-1. Higher levels of sFlt-1, but not PlGF, have previously been shown to independently predict adverse HF outcomes. 23 We determined that a substantial number of HF-Recovered patients had abnormal BNP, uric acid, ST2, and sFlt-1, defined as being above the 95th percentile, and nearly half had detectable troponin I. These findings suggest that there is persistent neurohormonal activation, increased oxidative stress, and cardiomyocyte injury and stress despite apparent recovery of EF. Although HF-Recovered patients had the best prognosis in terms of death, cardiac transplantation, and VAD placement, we note that the HF-Recovered patients did not, by any means, have a normal prognosis. Despite normalization of EF, these patients continued to experience substantial HF symptoms and clinical events, and the number of cardiac hospitalizations and symptomatology were similar to those of the HF-PEF population.
From a patient care perspective, these findings provide a rationale to continue background medical or device therapy for HF-Recovered patients. This recommendation is consistent with prior reports suggesting that the cessation of medical therapy was associated with a recurrence of LV dysfunction in patients who had previously improved or "recovered" their EF. 8, 24 In fact, we note that the majority of patients in our HF-Recovered group remained on medical therapy despite normalization of LV function. This is consistent with the idea that a recovery of EF does not necessarily constitute recovery from HF. For example, clinicians may have been reluctant to discontinue diuretics because of either previous failed attempts or persistent signs of volume overload such as lower-extremity edema or jugular venous distension.
Our observations are important to the interpretation of myocardial recovery versus remission or reverse remodeling. The HF-Recovered cohort, defined by echocardiographic measurement of EF, consists of patients who have a milder but persistent HF phenotype. However, we believe that this population represents a spectrum of patients exhibiting reverse remodeling (ie, improved ventricular function and milder clinical HF phenotype), a minority of whom have complete myocardial recovery, defined by normal chamber size, myocyte function, and neurohormonal profile, with freedom from future HF events. Distinguishing patients with complete myocardial recovery from those "in remission" represents an important clinical challenge because routine assessment of myocyte function at a cellular level is impractical in most patients. 12 This challenge underscores a need to identify biological characteristics and predictors of complete myocardial recovery within the reverse-remodeling or in-remission population indicative of the underlying mechanisms. Such an approach might include comprehensive biomarker panels, sophisticated imaging techniques (eg, magnetic resonance imaging, positron emission tomography scanning), and metabolomics. Additionally, insights from gene expression and micro-RNA analyses performed in LV assist device patients may provide additional information to characterize true recovery in non-VAD populations who are earlier in the disease course. 25 Our study has limitations. To begin our analysis, we chose to emulate a practical situation faced in clinical practice: what to do when the EF on echocardiography has normalized (eg, EF >50%) in a patient with HF-REF. Although EF is commonly used in clinical practice, it is at best a crude marker of cardiac function and remodeling because it does not properly capture other features such as absolute ventricular volumes, geometry, and ventricular-vascular coupling. In addition, there is no consensus on the appropriate definition or EF cutoff value for classification of patients as HF-PEF or HF-Recovered. 10, 26, 27 Current American Heart Association guidelines use an EF ≥50% for HF-PEF, noting the 41% to 49% category as intermediary with unclear pathophysiology. Sweitzer et al 28 demonstrated that patients with an EF of 40% to 55% are more similar to patients with an EF <40% than to those with a higher EF. Therefore, we chose an EF ≥50% for our HF-PEF and HF-Recovered groups. The determination of which "normal EF" patients to include in the HF-Recovery group (as opposed to HF-PEF) was based on a retrospective review of echocardiograms done before enrollment of the patient in this study. To guard against misclassification of patients as having HF-PEF, subjects were excluded if we could not identify previous echocardiograms to confirm a stable, preserved EF.
We note that the referral nature of this population provides both strengths and limitations. The strength is that the participants span a full spectrum of disease, including mild, moderate, and advanced HF. This allows us to compare findings across such subgroups using data from 3 US centers to make inferences about differences in disease mechanisms, pathophysiology, and outcome. We believe that these inferences are likely to be generalizable to similar populations with mild, moderate, and advanced HF but may not be extrapolated to the general population for the purpose of risk prediction. Additionally, the proportion of HF-PEF patients may be lower than what may be experienced in a general population because HF-REF patients are more likely to be referred to tertiary specialty centers. Despite these limitations, review of our table 1 findings shows typical features of HF-PEF in our HF-PEF subgroup, including a female bias, higher body mass index, and a high prevalence of hypertension and atrial arrhythmias. 29, 30 Finally, the effect of medication doses and the effect of cardiac resynchronization therapy were not analyzed as part of this study. This is due in part to lack of clear consensus on the appropriate medication regimen for true HF-PEF and for the HF-Recovered population. Nevertheless, the vast majority of patients across groups were on neurohormonal antagonists and diuretic therapy. Because of the relatively small size of our HF-Recovered cohort treated with cardiac resynchronization therapy (n=26), however, we have insufficient data to analyze predictors of cardiac resynchronization therapy response or to determine the specific prognosis of cardiac resynchronization therapy responders.
Conclusions
Our data suggest that the HF-Recovered EF population represents a distinct HF phenotype with biochemical properties and natural history that differ from the traditional HF-REF and HF-PEF populations. Furthermore, these patients continue to experience HF events, suggesting that this is not true myocardial recovery. Our study underscores the need to further investigate pathophysiological differences in these patient populations in an effort to better tailor therapy. It also highlights the need to identify characteristics and predictors of both reverse remodeling and myocardial recovery in the pre-LV assist device cardiomyopathy population.
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